Clinical Research Directory
Browse clinical research sites, groups, and studies.
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Sponsor: Hoag Memorial Hospital Presbyterian
Summary
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.
Official title: 2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid (PyL) in Patients With High Risk and Biochemically Recurrent Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
184
Start Date
2021-02-01
Completion Date
2022-12-15
Last Updated
2021-07-27
Healthy Volunteers
No
Conditions
Interventions
DCFPyL PET/CT
Prostate Membrane Specific Antigen-specific imaging
Locations (1)
Hoag Memorial Hospital Presbyterian
Irvine, California, United States